Boston Scientific Adds HabibTM EndoHPB Probe to Its Portfolio


Mar. 7 2018, Published 11:25 a.m. ET

An overview of EMcision

Boston Scientific (BSX) announced the acquisition of EMcision on March 5, 2018. EMcision is a privately held company based in the United Kingdom and Canada. The company’s flagship product, the HabibTM EndoHPB probe, is used during the treatment of pancreaticobiliary cancer. Pancreaticobiliary cancer patients often develop jaundice due to bile duct blockage as a result of tissue ingrowth in the GI (gastrointestinal) tract. The endoscopic bipolar radiofrequency device coagulates tissue in the GI tract to enable bile to drain out of the tract, which improves patients’ quality of life. The Habib EndoHPB probe is FDA approved and has CE Mark approval.

EMcision’s product portfolio has benefited more than 100,000 patients suffering from bile duct, liver, and pancreatic cancer around the world. The devices are sold in 38 countries.

Article continues below advertisement

Management view

According to Art Butcher, senior vice-president and president of Boston Scientific’s endoscopy division, “As we continue to search for ways to treat pancreaticobiliary cancers, we also seek to improve the quality of life for patients living with a cancer diagnosis today. We are committed to exploring innovative options to help increase the chance of early diagnosis, improve treatment and advance the ability to remove cancers located in challenging areas of the gastrointestinal tract.”

Some recent acquisitions in the endoscopy market include Medtronic’s (MDT) Crospon acquisition and Novadaq’s acquisition by Stryker (SYK). In early 2017, Cantel Medical (CMD) acquired some of CR Kennedy’s endoscopy assets.


More From Market Realist